Skip to main content

Tricyclic Antidepressants

Tricyclic antidepressants (TCAs) have several pharmacologic effects relevant to pain, sleep and the lower urinary tract, but the evidence differs greatly by indication. Amitriptyline is an AUA oral option for IC/BPS (Grade B). Imipramine has a US-labeled temporary adjunctive role in childhood enuresis from age 6. Low-dose doxepin is labeled for sleep-maintenance insomnia, not nocturia.[1][2][18]

For class-comparison context see SNRIs and Gabapentinoids. For the conditions these agents target, see IC/PBS, Chronic Pelvic Pain, and Nocturia.

Mechanism — Why TCAs Are Multifunctional in the LUT​

MechanismLUT effect
Antimuscarinic (competitive M-receptor antagonism)Reduces involuntary detrusor contractions and increases capacity. Imipramine, amitriptyline, nortriptyline, clomipramine all competitively antagonize ACh-induced bladder smooth-muscle contractions in isolated-tissue experiments[3][4][5]
5-HT and NE reuptake inhibitionModulates the micturition reflex at spinal and supraspinal levels. In rat experiments, acute imipramine raises the spinal reflex threshold (serotonergic), while chronic dosing raises the supraspinal threshold via a separate mechanism[6]
Direct smooth-muscle relaxationImipramine inhibits both bethanechol- and barium chloride–induced contractions — independent of antimuscarinic effect[5]
Norepinephrine reuptake at bladder neck / urethraProposed to increase urethral closure pressure, a historical rationale for SUI use and a theoretical concern in voiding dysfunction; a placebo-controlled single-dose study in 16 healthy women found no statistically significant increase in urethral opening pressure.[7][8][9][40]
Sodium channel blockadeAmitriptyline blocked rat skeletal-muscle sodium channels expressed in human embryonic kidney cells; a contribution to analgesia remains proposed.[51]
Central sleep / arousal modulationSleep/arousal effects have been proposed, but the mechanism of enuresis benefit is not established[10][11]

Agent comparison​

AgentPrimary urologic roleAnticholinergic potencyFDA urologic indication
ImipramineEnuresis; OAB/SUI use is historical and weakly supportedModerateYes — childhood enuresis[2]
AmitriptylineIC/BPS; selected neuropathic painHighest among TCAsNo
NortriptylineSelected neuropathic pain; historical frequency studiesLower than amitriptylineNo[16]
DoxepinInsomnia at low dose; historical DO studiesPotent antihistamine; Beers classifies doses above 6 mg/day as strongly anticholinergic in older adults and notes placebo-comparable safety at 6 mg/day or less[42]No; FDA-approved for insomnia at 3–6 mg[18]
DesipramineNeuropathic CPP componentLowest of the TCAsNo
ClomipramineOn-demand premature-ejaculation treatment (off-label); urinary-retention risk[48]HighNo

AUA/SMSNA 2020 recommends on-demand clomipramine among first-line PE medicines . Table 1 reports 25–50 mg on demand, and the Statement 9 discussion describes administration 3–6 hours before intercourse. Daily clomipramine 12.5–50 mg is also described in the discussion and table; the Statement 9 recommendation specifies on-demand use. The discussion favors SSRIs over clomipramine because of their better adverse-effect profile.[48]

IC/BPS — an oral option with mixed trial results​

The 2022 AUA IC/BPS Guideline lists amitriptyline as an oral medication option (Statement 14), alphabetically alongside cimetidine, hydroxyzine, and pentosan polysulfate, with no hierarchy.[1] Evidence Strength Grade B.[1][20]

Mechanism in IC/BPS​

Amitriptyline's antimuscarinic, monoaminergic, antihistaminic and sedating actions are proposed contributors to IC/BPS symptom relief.[20]

Pivotal RCT — van Ophoven 2004​

50 patients, prospective placebo-controlled double-blind, amitriptyline self-titrated 25 mg weekly to max 100 mg/day × 4 months:[14]

  • Mean combined O’Leary–Sant symptom/problem score: from 26.9 to 18.5 (amitriptyline) versus from 27.6 to 24.1 (placebo); p = 0.005
  • Pain and urgency intensity improved significantly (p < 0.001)
  • Anticholinergic adverse effects: 92% with amitriptyline versus 21% with placebo[14]

Treatment-naïve RCT — Foster 2010​

Multicenter (n = 271 treatment-naïve), amitriptyline escalated from 10 to 75 mg/day over 6 weeks plus standardized education / behavioral modification; primary outcome assessed after 12 weeks of treatment:[21]

  • Primary endpoint (moderate/marked GRA): 55% versus 45% (p = 0.12); not significant
  • Subgroup achieving ≥ 50 mg/day (n = 207): 66% versus 47% (p = 0.01); an unplanned subgroup analysis, influenced by dose tolerance and adherence[21]

Network meta-analysis 2021​

Amitriptyline significantly reduced the O’Leary–Sant symptom index (ICSI) versus placebo (MD −4.9, 95% CI −9.0 to −0.76); no agent significantly reduced 24-hour frequency. Certolizumab remains investigational for IC/BPS.[22]

AUA dosing​

Start 10 mg QHS; titrate according to benefit and tolerability, with 75–100 mg/day as the upper range discussed in the guideline, not a required target. Anticholinergic AEs are common (sedation, drowsiness, nausea) and frequently QoL-limiting.[1]

Nocturnal Enuresis — the only FDA-approved urologic indication​

Imipramine is FDA-approved as adjunctive therapy for nocturnal enuresis in children ≥ 6 years after organic causes are excluded.[2]

Dosing and monitoring​

Use the imipramine hub for age- and weight-limited dosing, ECG assessment and secure storage. The age-specific dose ceiling and 2.5 mg/kg/day limit both apply; long-term uninterrupted use is not established by the label.[2]

Cochrane 2016 evidence (64 trials, 4,071 children)[10][11]​

  • about 1 fewer wet night per week versus placebo (MD −0.95)
  • About 1 in 5 children become dry on imipramine
  • Across 12 trials (831 children), 78% on imipramine versus 95% on placebo failed to achieve 14 consecutive dry nights at treatment end (pooled RR 0.74)[10]
  • Imipramine plus oxybutynin: in one trial (47 children), 33% versus 78% on placebo failed to achieve 14 consecutive dry nights at treatment end (RR 0.43)[10]
  • High relapse on discontinuation

Safety[11][23]​

  • Cardiotoxicity. Arrhythmias, QT prolongation; obtain baseline ECG
  • Overdose lethality. TCAs are among the most dangerous drugs in overdose; ICCS recommends imipramine only after all other therapies have failed
  • Mood changes and sleep disturbance common
  • Store securely away from younger siblings

Current role​

For childhood enuresis, NICE recommends considering imipramine after all other treatments have failed and specialist assessment, and recommends against combining it with an anticholinergic for bedwetting.[11][23][50]

OAB / Detrusor Overactivity​

Antimuscarinic blockade, direct smooth-muscle effects, and central modulation of the micturition reflex provide mechanistic reasons to study TCAs for detrusor overactivity. Clinical efficacy is not established for the class.[7][24]

Selected evidence​

  • Castleden 1981. In an uncontrolled study of 10 elderly patients with unstable detrusor contractions, 6/10 became continent. Of six who underwent repeat cystometry, three showed increased capacity (mean +105 mL), lower bladder pressure at capacity (mean −18 cm H₂O), and increased urethral pressure (mean +30 cm H₂O).[9]
  • Lose 1989 (doxepin). Double-blind crossover RCT: 19 of 20 women with detrusor overactivity refractory to conventional therapy completed the study; during a 3-week doxepin period (50 mg QHS, with an optional 25 mg AM in week 3), nighttime micturitions and nighttime incontinence episodes decreased significantly versus placebo[17]
  • Servadio 1975 (nortriptyline). In an open three-week study, 40 women with long-standing frequency, urgency, and dysuria without a definite organic cause received nortriptyline; 75% had considerable improvement or resolution of urinary complaints. In vitro testing showed anticholinergic activity.[15]

Current role​

TCAs are not standard OAB pharmacotherapy. Modern antimuscarinics and β3-agonists have stronger direct evidence. OAB benefit from a TCA added for pain or psychiatric illness is unproven. NICE NG123 advises against offering imipramine to women with urinary incontinence or OAB (recommendation 1.4.28).[44][24][25][26][27]

Stress and Mixed Urinary Incontinence​

Imipramine's NE-reuptake inhibition at the bladder neck and proximal urethra was proposed to raise urethral closure pressure, a historical rationale for its off-label SUI use.[7][8][28]

Evidence​

  • Gilja 1984. 30 women with SUI on imipramine 75 mg/day × 4 weeks: self-reported continence in 21/30 (70%); functional urethral length extended and became independent of stress factors in responders[8]
  • A 2019 randomized crossover study in 16 healthy women found no significant or clinically relevant urethral-pressure increase after a single 50 mg imipramine dose.[40] Convincing randomized clinical efficacy is lacking.[40]

Mixed incontinence​

The dual antimuscarinic plus noradrenergic profile theoretically covers urge and stress components, but no head-to-head data support this in mixed UI.[28]

Comparison with duloxetine​

Duloxetine belongs to the SNRI class, not the TCAs. It has placebo-controlled randomized-trial evidence for SUI (small effect sizes) and a European SUI indication, but is not FDA-approved for SUI.[29] See the SNRI hub for benefit–harm counseling.[28]

CP/CPPS​

TCAs are part of the "N" (Neurologic / Systemic) domain of the UPOINT system for CP/CPPS, used for the neuropathic-pain component when present.[31]

AUA 2025 permits TCAs for neuropathic pain in CP/CPPS , but reports no TCA trials in men with CP/CPPS. Use draws on evidence from other neuropathic pain conditions.[43]

  • Cochrane 2019: antidepressants may be ineffective for prostatitis-symptom reduction (low- to very-low-quality evidence); GI discomfort, decreased libido, ejaculatory disorders, sedation, and dizziness were common AEs[30]
  • UPOINT-directed cohort studies report improvements with multimodal care[31]
  • Real-world prescribing pattern: in the Agarwal UCPPS comparison, 13.6% of gabapentin patients required adjunctive amitriptyline versus 44% of pregabalin patients (p = 0.0001); a retrospective prescribing observation[32]
  • TCAs are not first-line monotherapy; use as part of multimodal phenotype-directed therapy when neuropathic features, sleep disturbance, or comorbid depression are present[33]
  • EAU 2026 cites amitriptyline for neuropathic pain at 10–75 mg/day (sometimes up to 150 mg/day) taken at night and titrated to benefit and side effects, with nortriptyline or imipramine as alternatives, and states that evidence for CPPPS specifically is lacking and drawn largely from non-pelvic pain. It strongly recommends amitriptyline for primary bladder pain syndrome (level 1b).[47]

Chronic Pelvic Pain in Women​

SNRIs have ACOG support for neuropathic CPP.[12] SOGC Guideline No. 445 says tricyclic antidepressants should be considered for neuropathic pelvic pain, painful bladder syndrome (conditional recommendation; moderate-certainty evidence), and irritable bowel syndrome (strong recommendation; moderate-certainty evidence).[52] A 2009 randomized crossover trial showed gabapentin plus nortriptyline outperformed either alone for neuropathic pain.[49]

The 2021 JAMA CPP review states that anticonvulsants and antidepressants, including TCAs, can help associated mood, sleep and neuropathic pain symptoms, while providing only minimal pain improvement.[13]

For a confirmed neuropathic pain disorder, NICE lists amitriptyline, duloxetine, gabapentin or pregabalin as initial choices; no universal TCA-after-SNRI sequence is established. The cited combination trial involved diabetic neuropathy or postherpetic neuralgia, not pelvic pain.[41][13][49]

Vulvodynia​

Vulvodynia is a common reason to prescribe a TCA, but the two 12-week controlled trials below did not show a pain advantage for low-dose amitriptyline or desipramine over their comparators.[45][46] In Brown 2009 (53 women, 12 weeks), low-dose amitriptyline (10–20 mg/day), with or without topical triamcinolone, did not reduce pain significantly more than self-management.[45] In Foster 2010 (133 women, 12 weeks), desipramine and topical lidocaine, alone or combined, did not beat placebo on tampon-test pain, and every arm improved substantially. Use a TCA for a coexisting neuropathic or sleep component, set a time-limited trial, and stop if there is no functional gain.[45][46]

Nocturia and historical nonspecific LUT symptoms​

Doxepin 3–6 mg is FDA-approved for sleep-maintenance insomnia; the SILENOR label starts adults aged 65 years or older or those prone to urinary retention at 3 mg/day and limits dosing to 3 mg/day with cimetidine because exposure doubles.[18] Assess nocturnal urine production, bladder symptoms, sleep apnea and primary insomnia separately. Low-dose doxepin is contraindicated with severe urinary retention or untreated narrow-angle glaucoma and is ordinarily not recommended in severe sleep apnea.[18][34][35][37]

The 2004 amitriptyline IC/BPS trial did not significantly improve frequency or functional capacity versus placebo.[14][36] A separate 22-person retrospective series reported improvement in nonspecific frequency/pain.[14][36]

Urologic Adverse Effects — under-recognized​

Urinary retention in severe psychiatric-inpatient ADR surveillance​

  • In surveillance of 462,661 psychiatric inpatients (1993–2016), 129 severe urinary-retention events were recorded (0.028% of inpatients), the largest category among 171 severe urologic ADRs; TCAs had higher risk than other antidepressants, and amitriptyline and clomipramine were most often implicated in retention.[19]
  • Systematic review and meta-analysis: Antidepressants overall, not TCAs alone, were associated with more voiding disorders than placebo: OR 3.30 (95% CI 1.90–5.72)[38]

FDA-label urologic / sexual / endocrine effects (TCA class)[16][2][39]​

  • Urinary retention; delayed micturition; urinary tract dilation; paradoxical frequency at low doses
  • Decreased or increased libido; erectile dysfunction; testicular swelling; ejaculatory disorders; gynecomastia in males
  • SIADH / hyponatremia. Reported with all TCAs; clinically significant in elderly patients on diuretics; the amitriptyline label specifically warns about SIADH-related hyponatremia
  • Cardiovascular. QT prolongation, arrhythmias, heart block; obtain baseline ECG. Secondary amines may have lower relative anticholinergic effects, but nortriptyline and desipramine are still listed as strongly anticholinergic drugs to avoid in most older adults by Beers[42][16]

Practical prescribing and clinical positioning​

  • IC/BPS: amitriptyline is an option, with low-dose initiation and individualized titration.[1][21] Do not escalate solely to cross a supposed 50 mg efficacy threshold.[1][21]
  • Enuresis: imipramine has a temporary adjunctive indication, but relapse is common and cardiotoxicity/overdose risk reserve it for specialist use after safer established approaches. See the dedicated hub for dosing.[2][10][11]
  • Other pelvic pain: AUA 2025 permits neuropathic-pain drug classes for CP/CPPS ; response and functional benefit require reassessment.[41][43]
  • OAB/SUI/nocturia: historical small studies and mechanistic reasoning do not justify a routine TCA prescribing regimen.[9][17][40]

Safety before and during treatment​

TCAs can cause retention, constipation, cognitive impairment, orthostatic symptoms and cardiac conduction toxicity. Assess cardiac history and interacting medicines; ECG monitoring should reflect age, cardiac risk, dose, and the specific product. Nortriptyline should generally be avoided in patients with known or suspected Brugada syndrome.[16] Acute post-MI use is contraindicated or not recommended depending on the TCA label. Avoid MAOI combinations and observe the product’s washout instructions, including special precautions with linezolid or IV methylene blue. Monitor mood, suicidality and possible bipolar activation; antidepressant labels carry a suicidality boxed warning. Prescribe limited quantities when overdose risk exists and taper when stopping. Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine, some antiarrhythmics) raise TCA levels; the nortriptyline label advises plasma-level monitoring when it is combined with a 2D6 inhibitor. The amitriptyline label's 10 mg three times daily plus 20 mg at bedtime example for older or adolescent patients describes depression treatment, not IC/BPS initiation.[39] For IC/BPS, the AUA guideline describes starting at about 10 mg daily and titrating to benefit and tolerability.[1] The nortriptyline label calls for the smallest effective dose in older adults.[2][16][39][1]

A lower relative anticholinergic effect does not make nortriptyline or desipramine safe by default in an older patient. Beers includes both, alongside amitriptyline and imipramine, among strongly anticholinergic antidepressants; doxepin ≤6 mg/day is the low-dose exception, used for insomnia with its own precautions.[18][42]

See Also​

References​

1. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

2. DailyMed. Imipramine hydrochloride: prescribing information. Label. Accessed September 12, 2026.

3. Uno J, Obara K, Suzuki H, et al. "Inhibitory effects of antidepressants on acetylcholine-induced contractions in isolated guinea pig urinary bladder smooth muscle." Pharmacology. 2017;99(1-2):89–98. doi:10.1159/000452221

4. Rehavi M, Weiss H, Nissenkorn I, Rubinstein R, Cohen S. "A comparative study of the affinities of some tricyclic antidepressants for the muscarinic cholinergic receptor in human and guinea-pig bladder, ileum and brain in relation to differential drug potency." Life Sci. 1987;40(18):1819–1827. doi:10.1016/0024-3205(87)90093-2

5. Benson GS, Sarshik SA, Raezer DM, Wein AJ. "Bladder muscle contractility: comparative effects and mechanisms of action of atropine, propantheline, flavoxate, and imipramine." Urology. 1977;9(1):31–35. doi:10.1016/0090-4295(77)90279-5

6. Maggi CA, Borsini F, Lecci A, et al. "Effect of acute or chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats." J Pharmacol Exp Ther. 1989;248(1):278–285. doi:10.1016/s0022-3565(25)23645-x

7. Sullivan J, Abrams P. "Pharmacological management of incontinence." Eur Urol. 1999;36(Suppl 1):89–95. doi:10.1159/000052327

8. Gilja I, Radej M, Kovacić M, Parazajder J. "Conservative treatment of female stress incontinence with imipramine." J Urol. 1984;132(5):909–911. doi:10.1016/s0022-5347(17)49941-1

9. Castleden CM, George CF, Renwick AG, Asher MJ. "Imipramine — a possible alternative to current therapy for urinary incontinence in the elderly." J Urol. 1981;125(3):318–320. doi:10.1016/s0022-5347(17)55023-5

10. Caldwell PHY, Sureshkumar P, Wong WCF. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev. 2016;1:CD002117. doi:10.1002/14651858.CD002117.pub2.

11. Robson WL. "Evaluation and management of enuresis." N Engl J Med. 2009;360(14):1429–1436. doi:10.1056/NEJMcp0808009

12. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

13. Lamvu G, Carrillo J, Ouyang C, Rapkin A. "Chronic pelvic pain in women: a review." JAMA. 2021;325(23):2381–2391. doi:10.1001/jama.2021.2631

14. van Ophoven A, Pokupic S, Heinecke A, Hertle L. "A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis." J Urol. 2004;172(2):533–536. doi:10.1097/01.ju.0000132388.54703.4d

15. Servadio C, Nissenkorn I, Zeigler M. "Nortriptyline hydrochloride in urology." Urology. 1975;5(6):747–750. doi:10.1016/0090-4295(75)90345-3

16. DailyMed. Nortriptyline hydrochloride: prescribing information. Label. Accessed September 12, 2026.

17. Lose G, Jørgensen L, Thunedborg P. "Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study." J Urol. 1989;142(4):1024–1026. doi:10.1016/s0022-5347(17)38976-0

18. Currax. SILENOR (doxepin): prescribing information. DailyMed. Accessed September 12, 2026.

19. Winkler D, Grohmann R, Friedrich ME, et al. "Urological adverse drug reactions of psychotropic medication in psychiatric inpatients — a drug surveillance report from German-speaking countries." J Psychiatr Res. 2021;144:412–420. doi:10.1016/j.jpsychires.2021.10.026

20. Chermansky CJ, Guirguis MO. "Pharmacologic management of interstitial cystitis / bladder pain syndrome." Urol Clin North Am. 2022;49(2):273–282. doi:10.1016/j.ucl.2022.01.003

21. Foster HE, Hanno PM, Nickel JC, et al. "Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis / painful bladder syndrome." J Urol. 2010;183(5):1853–1858. doi:10.1016/j.juro.2009.12.106

22. Di XP, Luo DY, Jin X, et al. "Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis." Int Urogynecol J. 2021;32(5):1129–1141. doi:10.1007/s00192-020-04659-w

23. Lauters RA, Garcia KW, Arnold JJ. "Enuresis in children: common questions and answers." Am Fam Physician. 2022;106(5):549–556. PMID 36379501

24. Andersson KE. "Treatment of overactive bladder: other drug mechanisms." Urology. 2000;55(5A Suppl):51–57. doi:10.1016/s0090-4295(99)00495-1

25. Wein AJ. "Pharmacologic options for the overactive bladder." Urology. 1998;51(2A Suppl):43–47. doi:10.1016/s0090-4295(98)90009-7

26. Athanasopoulos A. "The pharmacotherapy of overactive bladder." Expert Opin Pharmacother. 2011;12(7):1003–1005. doi:10.1517/14656566.2011.554397

27. Loloi J, Clearwater W, Schulz A, Suadicani SO, Abraham N. "Medical treatment of overactive bladder." Urol Clin North Am. 2022;49(2):249–261. doi:10.1016/j.ucl.2021.12.005

28. Norton P, Brubaker L. "Urinary incontinence in women." Lancet. 2006;367(9504):57–67. doi:10.1016/S0140-6736(06)67925-7

29. Wu JM. "Stress incontinence in women." N Engl J Med. 2021;384(25):2428–2436. doi:10.1056/NEJMcp1914037

30. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis / chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

31. Polackwich AS, Shoskes DA. "Chronic prostatitis / chronic pelvic pain syndrome: a review of evaluation and therapy." Prostate Cancer Prostatic Dis. 2016;19(2):132–138. doi:10.1038/pcan.2016.8

32. Agarwal MM, Elsi Sy M. "Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin?" Neurourol Urodyn. 2017;36(8):2028–2033. doi:10.1002/nau.23225

33. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. "Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome." Drugs Aging. 2021;38(10):845–886. doi:10.1007/s40266-021-00890-2

34. Morin CM, Buysse DJ. "Management of insomnia." N Engl J Med. 2024;391(3):247–258. doi:10.1056/NEJMcp2305655

35. Morin CM, Benca R. "Chronic insomnia." Lancet. 2012;379(9821):1129–1141. doi:10.1016/S0140-6736(11)60750-2

36. Pranikoff K, Constantino G. "The use of amitriptyline in patients with urinary frequency and pain." Urology. 1998;51(5A Suppl):179–181. doi:10.1016/s0090-4295(98)00071-5

37. Kim J, Chung E. "Pharmacotherapeutic options in the treatment of nocturia: an update on the current oral drug therapies." Expert Opin Pharmacother. 2022;23(3):405–411. doi:10.1080/14656566.2021.2016698

38. Trinchieri M, Perletti G, Magri V, et al. "Urinary side effects of psychotropic drugs: a systematic review and metanalysis." Neurourol Urodyn. 2021;40(6):1333–1348. doi:10.1002/nau.24695

39. DailyMed. Amitriptyline hydrochloride: prescribing information. Label. Accessed September 12, 2026.

40. Kornholt J, Sonne DP, Riis T, Sonne J, Klarskov N. Effect of imipramine on urethral opening pressure: a randomized, double-blind, placebo-controlled crossover study in healthy women. Neurourol Urodyn. 2019;38:1076–1080. doi:10.1002/nau.23955.

41. NICE. Neuropathic pain in adults: pharmacological management (CG173). Recommendations.

42. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71:2052–2081. doi:10.1111/jgs.18372.

43. Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part II Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. J Urol. 2025;214(2):127-137. doi:10.1097/JU.0000000000004565 Full 2025 guideline

44. National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management (NG123). 2019. Recommendation 1.4.28. NICE

45. Brown CS, Wan J, Bachmann G, Rosen R. Self-management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. J Womens Health (Larchmt). 2009;18(2):163-9. doi:10.1089/jwh.2007.0676

46. Foster DC, Kotok MB, Huang LS, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol. 2010;116(3):583-593. doi:10.1097/AOG.0b013e3181e9e0ab

47. Engeler D, Baranowski AP, Berghmans B, et al. EAU Guidelines on Chronic Pelvic Pain. European Association of Urology; limited update March 2026. Guideline

48. Shindel AW, Althof SE, Carrier S, et al. Disorders of Ejaculation: An AUA/SMSNA Guideline. J Urol. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392 (2020 guideline, Statement 9, discussion and Table 2).

49. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009;374(9697):1252-1261. doi:10.1016/S0140-6736(09)61081-3

50. National Institute for Health and Care Excellence. Bedwetting in under 19s: diagnosis and management (CG111). 2010. Recommendations 1.13.7 and 1.14.3. Guidance.

51. Wang GK, Russell C, Wang SY. "State-dependent block of voltage-gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain." Pain. 2004;110(1-2):166–174. doi:10.1016/j.pain.2004.03.018

52. Allaire C, Yong PJ, Bajzak K, et al. "Guideline No. 445: Management of Chronic Pelvic Pain." J Obstet Gynaecol Can. 2024;46(1):102283. doi:10.1016/j.jogc.2023.102283